10/15/2012 8:23:49 AM
My e-mail inbox has been filled with some very bullish takes on Eli Lilly and its Alzheimer’s drug solanezumab. There’s also a lot of excitement about the idea that the patent for Alimta, a top-selling cancer drug, might hold up in court, extending a very profitable franchise for the drug maker. But here is the opposite take, from Cowen and Co. analyst Steven Scala who downgraded Lilly stock to underperform today.
comments powered by